GSK, Amgen and AstraZeneca released positive data supporting their rival drugs in a condition called chronic rhinosinusitis ...

Pliant Therapeutics discontinues Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis due to safety concerns, but ...

Biohaven’s potassium channel drug has failed a late-stage study in bipolar mania, according to a statement in the company’s ...

Protagonist Therapeutics reported a clean Phase 3 win on Monday for rusfertide — its rare blood disorder therapy — putting it ...

M223, a preclinical drug for inflammatory diseases, with potential milestone payments of $777.5M plus royalties.

Nuvation Bio gets $250M total funding for taletrectinib commercialization & pipeline; Syros to delist from Nasdaq on March 20 after January compliance warning ...

Frazier Life Sciences and a cadre of well-known biotech investors are coming together for a new startup in the antibody-drug ...

Neumora pauses two Phase 3 trials of navacaprant for depression after earlier trial failure, CEO Paul Berns makes changes to ...

Lexicon's non-opioid drug pilavapadin fails Phase 2b pain trial at 20mg dose, but shows promise at 10mg. Company plans Phase ...

For years, artificial intelligence has been a topic of discussion in pharmaceutical manufacturing, but adoption has been slow ...

AbbVie becomes an obesity contender as it partners with Danish biotech Gubra in $350M upfront deal for amylin analog GUBamy, ...

Biotech investing saw growth in 2024, with RA Capital leading VCs. FDA cancels flu vaccine meeting, Pfizer hires ex-FDA ...